Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Street Walker who wrote (2339)	2/29/2000 5:27:00 PM
From: Cameron Dorey	Read Replies (3) \| Respond to of 5582

Is there any sense to pointing us to this story which is over 7 months old? I don't understand. Cameron

To: Street Walker who wrote (2339)	2/29/2000 5:27:00 PM
From: Ed Person	Respond to of 5582

SW, Do you have a date for the next earnings release? Thanks, Ed

To: Street Walker who wrote (2339)	3/2/2000 1:20:00 AM
From: Street Walker	Read Replies (1) \| Respond to of 5582

Rigorous data ends up in Medical Journals. Medical Journals give substance to medical claims. Allows for acceptance by the medical community and gives credance to Advertising Statements to sell more product for years on out. Zicam becomes a Household Name. Medical Journals also get the attention of the national media (TV and Investment papers, even local newspapers) if there is enough human interest, inwhich I believe the common cold has. There is a story that will be told, massive buyers will come, and there will be upcoming quarterly earnings which will support much higher prices as the Growth of Zicam is realized. Each year Zicam will penetrate further and further into the US $3 Billion otc remedy market. I don't know how big the international market is, and that's our next step. OLD NEWS --- Initial clinical research has indicated that use of ZICAM(TM) can reduce the duration of the common cold from 12 -- 14 days to 1 -- 3 days. According to R. Steven Davidson, CEO of Gel Tech, "Scientists at two major universities have begun work on the next phase of clinical research concerning the efficacy of ZICAM(TM). The research will have three objectives: confirming ZICAM(TM)'s ability to significantly reduce the duration of the common cold; exploring ZICAM(TM)'s ability to act as a preventive measure against the common cold and its symptoms; and testing ZICAM(TM)'s ability to relieve symptoms caused by allergic reactions to common airborne allergens." Davidson continued, "The independent studies will be conducted at multiple sites according to rigorous scientific protocols. The research on ZICAM(TM)'s therapeutic and preventive benefits will be conducted by inoculating patients with a common strain of rhinovirus." Davidson concluded, "Baring unforeseen delays, we anticipate that the research will be completed by the end of October, 1999."